		us	Patent and Ti	Approved for	or use through 07/31/20 Pfice; U.S. DEPARTME	PTO/SB/21 (0 106. OMB 0551 NT OF COMM	-0031
Under the Paperwork Reduction Act of 1995				ormation un			
TRANSMITTAL	Fili	ng Date	July 22, 20				
FORM		st Named Inventor	<del></del>	HARKINS. Richard et al.			
·	Art	Unit	1643	, raciiala el	A	<b>ECEIVE</b>	$\vdash$
	Ex	aminer Name	-		CENTR	AL FAX CE	NTE
(to be used for all correspondence after initial	filing)		BLANCH	ARD, David	J.		
Total Number of Pages in This Submission	3 All	orney Docket Number	51791AU	JSC1	MA	1 9 200	16/
	ENCLOS	URES (Check a	il that apply				
Fee Transmittal Form	Drawi	ing(s)			After Allowance Con		o IC
Fee Attached	Licen	sing-related Papers		- '	Appeal Communicat of Appeals and Inter	ferences	
✓ Amendment/Repty	Petitio	on			Appeal Communicat (Appeal Notice, Brief,	ion to TC Repty Brief)	
After Final		on to Convert to a sional Application			Proprietary Informat	on	
	Powe	er of Attorney, Revocati			Status Letter		
Affidavlts/declaration(s)		ige of Correspondence	Address		Other Enclosure(s)	please Identi	fv
Extension of Time Request	Term	inal Disclaimer			below):		•
Express Abandonment Request	Requ	est for Refund		1			
Information Disclosure Statement	CD.	Number of CD(s)					
		Landscape Table on (	20	ŀ			
Certified Copy of Priority	Benedi	Lanuscape rable on C		<u> </u>			
Document(s)	Remarks						
Reply to Missing Parts/							
Incomplete Application Reply to Missing Parts	i			•			
under 37 CFR 1.52 or 1.53	1						
SIGNA	TURE OF A	APPLICANT, ATT	ORNEY,	OR AGE	NT		
Firm Name BERLEX BIOSCIENCES	3	<del></del>					
Signature Wenny - We	voutier						
Printed name WENDY L. WASHTIEN,	, PH.D.						
Date May 19, 200	May 19, 2006			36,301			
	ERTIFICAT	E OF TRANSMIS	SION/MA	ILING			
I hereby certify that this correspondence is sufficient postage as first class mail in an eithe date shown below:							
Signature	Llon	10/	~				
Typed or printed name MARY ANN FL	OFES			T	Date Man	19,2	206
	<del>/</del>						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.4. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form endfor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Depertment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.

**△**002/003

10/624,884

Casc 51791AUSC1

RECEIVED **CENTRAL FAX CENTER** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Harkins et al.

Serial No. 10/624,884

Filed July 22, 2003

Group Art Unit 1643

Examiner: David J. Blanchard

For DNA ENCODING A NOVEL RG1 POLYPEPTIDE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

## RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

This communication is in response to the Restriction Requirement dated May 3, 2006.

The Examiner has required restriction to one of the following groups:

Group I. Claims 1-25, drawn to an antibody and immunoconjugate that binds an RG1 polypeptide.

Group II. Claim 26, drawn to a method of selectively destroying RG1 expressing cells with an immunoconjugate that binds the RG1 polycptide.

Claims 27-29, drawn to a method of treating a disease in a human patient, Group III. wherein the disease is associated with expression of an RG1 polypeptide

51791AUSC1rr

10/624,884

2

51791AUSC1

comprising administering an immunoconjugate that binds RG1 polypeptide.

Group IV. Claims 30-35, drawn to a method of detecting a disease associated with the expression of an RG1 polypeptide in a subject comprising administering an RG1 specific immunoconjugate, detecting binding of the immunoconjugate and determining the level of binding of the immunoconjugate compared with the level of binding in disease-free subjects.

Applicants elect Group I, Claims 1-25, drawn to an antibody and immunoconjugate that bind to an RG1 polypeptide. Should these product claims be found allowable, the withdrawn process claims should be rejoined.

Applicants reserve the right, under 35 U.S.C. 120, to pursue the non-elected subject matter of Groups II-IV in separate divisional applications.

This response is timely filed. Therefore, we believe no fee is due. However, the Commissioner is hereby authorized to charge deposit account 02-2117 for any fees necessary. This is not, however, authorization to charge the issue fee. Two copies of this paper are enclosed for this purpose.

Respectfully submitted.

Wendy L. Washtien, Ph.D.

Agent for Applicant Reg. No. 36,301

Berlex Biosciences 2600 Hilltop Drive P.O. Box 4099 Richmond, CA 94804-0099 Telephone: (510) 262-5411

Fax: (510) 262-7095 Date: May 19, 2006

51791AUSC1π